

Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

CARLSBAD, Calif., Oct. 13, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will present preclinical data on TYRA-200 during a poster session at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 26-28, 2022, in Barcelona, Spain.

Details of the poster presentation are as follows:

Title: TYRA-200: Potent Against FGFR2 Fusions, Molecular Brake Mutations and Gatekeeper Resistance

Date/Time/Location: Wednesday, October 26, 2022, 12-20:00 CET, Exhibition Hall

Session/Session Code: Molecular Targeted Agents 1, PP20

Poster #: 47

Regular abstracts are available on the EORTC-NCI-AACR website. The poster on TYRA-200 will be made available on the TYRA website under the "For Investors" section on October 26, 2022.

About Tyra Biosciences

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA's proprietary in-house discovery platform, SNĀP, enables the rapid and precise refinement of structural design through iterative molecular SNĀPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Leveraging SNĀP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers. TYRA-300 is an FGFR3 selective inhibitor for oncology. TYRA-200 is an FGFR1/2/3 inhibitor with potency against FGFR2 fusions, molecular brake mutations and gatekeeper resistance that TYRA is developing initially in intrahepatic cholangiocarcinoma. TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and REarranged during Transfection kinase (RET) related cancers. TYRA is based in Carlsbad, CA. For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on [LinkedIn](#).

Contact:

Amy Conrad
aconrad@tyra.bio

SOURCE Tyra Biosciences, Inc.

<https://tyrabio.investorroom.com/2022-10-13-Tyra-Biosciences-to-Present-Preclinical-Data-on-TYRA-200,-an-FGFR1-2-3-Inhibitor,-at-34th-EORTC-NCI-AACR-Symposium-on-Molecular-Targets-and-Cancer-Therapeutics>